Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

L.S. Schneider, R.E. Kennedy, G.R. Cutter, N.C. Fox

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)367-377
JournalAlzheimers & Dementia
Volume6
Issue number5
DOIs
Publication statusPublished - 2010

Cite this